• Actavis Inc., of Parsippany, N.J., reached a settlement agreement with Shire plc, of Dublin, Ireland, resolving patent litigation related to Actavis' generic version of INTUNIV (guanfacine hydrochloride) to treat attention deficit hyperactivity disorder. In October 2012, the FDA granted approval of Actavis' abbreviated new drug application.